

Adherence To Antipsychotic Medications for Individuals with Schizophrenia

CBH is committed to ensuring members receive quality care. Monitoring adherence to medications is one such way to improve quality of care. Members with a diagnosis of schizophrenia spectrum and psychotic disorders require adherence to medications for adequate symptom and disease management. Adherence to antipsychotic medications may reduce psychiatric morbidity and cost of care. Providers play a crucial role in supporting members' adherence to medications.

For more information, see the [National Committee for Quality Assurance \(NCOA\) Behavioral Health Resource Center](#).

Best Practices

- ➔ Assess members' adherence at each visit. Use a tool such as the [M.A.R.S. Calculator](#).
- ➔ Ensure member has an adequate supply of medications and refills.
- ➔ Share the [CBH Antipsychotic Medication Guide](#) with your members.
- ➔ Address members' specific barriers to antipsychotic adherence. Refer to the [PA DHS Preferred Drug List](#) to see which medications are preferred.
- ➔ Assess if member is a candidate for a long-acting injectable (LAI) antipsychotic to improve adherence. Refer to CBH's [Pharmacy Resources for Providers webpage](#).
- ➔ Engage in shared decision-making such that members are at the center of care. Learn more in [SAMHSA: Shared Decision-Making in Mental Health Care](#).
- ➔ Collaborate with the member's primary care physician.

Diagnoses Associated with this Measure

- ➔ [F20.0] Paranoid Schizophrenia
- ➔ [F20.1] Disorganized Schizophrenia
- ➔ [F20.2] Catatonic Schizophrenia
- ➔ [F20.3] Undifferentiated Schizophrenia
- ➔ [F20.5] Residual Schizophrenia
- ➔ [F20.81] Schizophreniform Disorder
- ➔ [F20.89] Other Schizophrenia
- ➔ [F20.9] Schizophrenia, Unspecified
- ➔ [F25.0] Schizoaffective Disorder, Bipolar Type
- ➔ [F25.1] Schizoaffective Disorder, Depressive Type
- ➔ [F25.8] Other Schizoaffective Disorders
- ➔ [F25.9] Schizoaffective Disorder, Unspecified

HealthChoices Preferred Drug List

For reference, see the [PA Statewide Preferred Drug List \(PDL\)](#).

First-Generation Antipsychotics:

Fluphenazine, Haloperidol, Loxapine, Perphenazine, Trifluoperazine

Second-Generation Antipsychotics:

Aripiprazole, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone

Adherence To Antipsychotic Medications for Individuals with Schizophrenia

Resources

- ➔ [CBH: HEDIS Tip Sheets](#)
- ➔ [CBH: Pharmacy Resources for Members](#)
- ➔ [CBH: Pharmacy Resources for Providers](#)
- ➔ [PA Medical Assistance Preferred Drug List \(PDL\)](#)
- ➔ [SAMHSA: Shared Decision-Making in Mental Health Care](#)
- ➔ [NCOA Supports Medicaid Behavioral Measure Reporting](#)
- ➔ [Medication Adherence Rating Scale \(M.A.R.S.\) Calculator](#)
- ➔ [CMS: Measures Inventory Tool](#)
- ➔ [CDC: A1C Test for Diabetes and Prediabetes](#)

Lab Coverage Information

Health Plan	Laboratory Provider
Community Behavioral Health	Atlantic Diagnostic Laboratories Parkway Clinical Laboratories
Jefferson Health Plans	Quest Diagnostics
Keystone First	LabCorp
United Healthcare	LabCorp Quest Diagnostics
Gelsinger	LabCorp Quest Diagnostics Jefferson Health
PA Health and Wellness	LabCorp Quest Diagnostics
UPMC	Quest Diagnostics

Disclaimer: The information contained in this tip sheet is for educational and informational purposes only. The clinical services described in this tip sheet may not be covered for all CBH enrollees. To find out about what services are available to you under the CBH benefit package, please contact CBH Provider Operations at 215-413-3100.